Collplant Holdings ADR Stock News

Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center scheduled to become operational this quarter and under new commercial leadership for this region Recent developments suggest CollPlant's rhCollagen will have a significant contribution towards innovation in the areas of non-animal alternatives...

REHOVOT, Israel , Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 26, 2025, bef...

-- New North American logistics center will provide expanded distribution for CollPlant's rhCollagen and BioInks as well as enable logistical efficiencies -- REHOVOT, Israel , Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rh...

A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D ™, outperformed Matrigel®, a leading extracellular matrix, in supporting structured tissue formation. The findings suggest Collink.3D ™ could offer a consistent, tunable, and animal-free alternative for advanced tissue engineering and research applications.

The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research. According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers combines CollPlant's plant-derived recombinant human collagen (rhCollagen) with distinct and essential human skin cell types.

CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel , Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human collagen (rh...

REHOVOT, Israel , Sept. 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its European distribution network for Vergenix™ STR through the signing o...

REHOVOT, Israel , Sept. 2, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced its participation in the annual meeting of The International Society of Biofabrication: the International Conference on Biof...